Jatenergy Limited (ASX: JAT) is an export service provider for the Australian companies looking forward to launching and build their brands in the Chinese market.
On 12 April 2019, the company notified the market that Sunnya Pty Ltd (Sunnya), its subsidiary, would be opening a new market section, with an innovative premium nutritional product for the rapidly budding middle-aged market in Australian, Chinese and other Asian region markets.
Sunnya Pty Ltd taps a new market segment, with the launch in mid-May 2019 of new premium milk product, named Neurio Middle-Aged Formulated Nutritional Powder with Lactoferrin. The product will be launched in Australia, China, Korea, and Hong Kong, with negotiations currently being underway in Japan and Vietnam.
The new product provides a broad array of health benefits based on ingredients carefully selected and would also supplement calcium, iron, zinc as well as essential vitamins. It is a pioneering product specifically designed for people aged 40- plus with carefully selected, health-promoting ingredients. The new range will be sold throughout Sunnya’s extensive network of distributors, which includes retail outlets and cross border e-commerce platforms.
Daisy Lu, Sunnya Pty Ltd’s MD said that innovation is the key pillar supporting Sunnya’s growth and success in the Australian and Chinese markets. This latest announcement significantly advances its reach into the Chinese market. She further added that the Sunnya’s continuous innovation is driven by its deep expertise in the benefits and use of lactoferrin, a monomeric glycoprotein with immunological activity derived from milk, in health products.
Sunnya is into developing new health products and formulations to diversify into different market segments and gratify the requirements of several age groups for premium health products. Sunnya anticipates its present sales network for Neurio products, well established in China through a series of valuable agreements, to expand into a variety of nations.
Sunnya has attained solid interest from retailers across Chinese region, and it is anticipating getting orders when the product is available to the market, in mid-May 2019. Some of the retailers in China anticipated to place orders include: Babemax, Shanghai Dragon Stores, Pharmacies, such as Sinopharm and many more.
The new product would be available for sale online via Woolworths Tmall Global Flagship Store, Xiaohongshu, Wanwustore, Hipac, Tomtop and many more platforms.
In its half-year report for the period ending on 31 December 2018, the company recorded the revenue from ordinary activities for the period standing at $30 million, an outstanding 1834% jump from $1.5 million in the previous corresponding period (pcp). However, the net loss from ordinary operating activities after tax was noted at $21 million from 0.27 million in the pcp. The net loss from ordinary operating activities after tax attributable to members of the Parent stood at $10 million from 0.26 million in the pcp. The loss per share stood at 20.90 cents down by 2123% from 0.94 cents in the pcp. The net tangible assets per ordinary share stood at 0.031 cents, down by 44% from 0.055 in the pcp.
During the period, JAT concluded two significant acquisitions by acquiring 50% of Green Forest International Pty Ltd on 18 July 2018. On 10 October 2018, JAT further widened its in-house product range by buying 51% of Sunnya Pty Ltd.
On 4 April 2019, the company announced that it had signed MOU with HIT Crown.
The stock of the company closed the day’s session at a price of A$0.058, down by 1.7% (as on 12 April 2019). The stock has provided a decent return of 47.50% over last six months, however, last one month stock price has risen marginally by 3.51%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.